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Abstract
Background: The most important factors that affect the incidence of vaccine-related complications are the
constituent biological components of the vaccine, injection site reactions, age and sex. The aim of this study is to
determine the incidence rate of adverse events following immunization with pentavalent vaccine (DTPw-Hep B-Hib
(PRP-T) vaccine (pentavac) (adsorbed) is manufactured by Serum Institute of India ltd), which was introduced in Iran
in November 2014. It is important to monitor vaccine-related adverse events because of the role of vaccine safety
in immunization program success.
Methods: This study was a mixed cohort study that included 1119 children less than 1 year of age. In 2015, the
children were referred to Hamadan health centers to receive pentavalent vaccine at 2, 4 and 6 months of age. The
data were collected from the parents of the children using a questionnaire that was administered either face-to-face or
by telephone. The cumulative incidence of side effects and risk ratio was reported with 95% confidence intervals (CI).
Chi-squared tests and logistic regressions were used to investigate the association between the variables.
Results: The cumulative incidence rate of pentavalent-related adverse events during 48 h following immunization was
estimated to be 15.8% for swelling, 10.9% for redness, 44.2% for pain, 12.6% for mild fever, 0.1% for high fever, 20.0%
for drowsiness, 15.0% for loss of appetite, 32.9% for irritability, 4.6% for vomiting and 5.5% for persistent crying. There is
no evidence for the occurrence of convulsion and encephalopathy among children who receive pentavalent vaccines.
Conclusion: Further large studies with long time follow up are required to address rare events include convulsions,
encephalopathy or persistent crying. However, Findings urge immunization programs to use pentavalent vaccinations
and to continue implementing the current immunization program in children under 1 year of age.
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Background
Immunization is a fundamental component of public
health policies for controlling infectious diseases. The
vaccination program for smallpox effectively eradicated
the disease from the world. Moreover, similar vaccin-
ation programs successfully led to the regional eradica-
tion of other infectious diseases, making vaccination one
of the most reliable and cost-effective public health
interventions [1]. According to estimations made by the
World Health Organization (WHO), approximately two
million deaths among children under 5 years of age can
be prevented annually through the use of existing
vaccines [2]. WHO has recommended the Expanded
Program on Immunization (EPI), which integrates
Heamophilus influenza type b (Hib) vaccine into the
routine pediatric immunization program. Hib is a
leading cause of life-threatening infectious diseases, in-
cluding meningitis and pneumonia, that mostly affects
children under 5 years of age [3, 4]. Hib is responsible
for a significant proportion of the disease burdens of
both developed and developing countries. Each year, Hib
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leads to approximately three million cases of serious ill-
ness and 400,000 to 700,000 deaths among children [5].
Some new vaccines, especially multivalent ones, have
been added to the immunization program, primarily to
add more antigens to vaccines. For example, in most
countries, the tetravalent (DTP-Hib or DTP–HepB) or
pentavalent (DTP-HepB-Hib) combination vaccines are
currently being used instead of the trivalent vaccine
(DTP) without the Hib or HepB component [6]. Com-
bination vaccines for pediatric immunization schedules
have contributed to a decrease in the number of clinic
visits, logistical challenges, operational costs and injec-
tions and an increase in parental consent [7, 8]. More-
over, these vaccines improve individual adaptation to the
virus and routine vaccination coverage. Therefore, the
addition of antigens to existing vaccines with high cover-
age is considered an effective and appropriate strategy
for protecting society from new diseases [9, 10].
Public trust in newly introduced vaccines can be
strengthened by monitoring vaccine safety. Surveillance of
adverse events following immunization will enable us to
monitor the safety of immunization programs and thereby
contribute to validating the immunization program. In
this way, the undesirable adverse events of the
immunization program can be effectively managed, and
any inappropriate measures based on reports of adverse
effect that may cause concern in society can be prevented
[11–13]. As the pentavalent vaccine (DTPw-Hep B-Hib
(PRP-T) vaccine (pentavac) (adsorbed) manufactured by
Serum Institute of India ltd) has been part of the national
pediatric immunization schedule of Iran since 2014, the
study of adverse events associated with this vaccine seems
to be of paramount importance. After assessing for reacto-
genicity following immunization with the pentavalent vac-
cine, we can take effective and useful action toward
earning public trust and managing vaccine safety.
The aim of this study is to examine pentavalent vaccine
safety and increase the amount of knowledge that might
help policy makers in their decisions to continue introdu-
cing pentavalent vaccines to immunization programs.
Methods
The sample of the present mixed cohort study was com-
prised of 1119 children under 1 year of age who were re-
ferred to Hamadan health centers to receive pentavalent
vaccine at 2, 4 and 6 months of age. More specifically, a
sample of approximately 370 children was examined at
each point of the three scheduled doses of pentavalent
vaccine. Only children under 1 year of age who received
the first, second and third dose of pentavalent vaccine
were eligible for inclusion in this study.
Urban health centers that are affiliated with the
District Health Center in the city of Hamadan were
selected using a randomized sampling method, and
children under 1 year of age who were referred to these
centers to receive pentavalent vaccine at 2, 4 and
6 months of age were recruited consecutively.
The data for the present study were collected through
a self-constructed questionnaire from the parents of the
children. Ethical approval for the present study was
obtained from the Ethics Committee of the Hamadan
University of Medical Sciences. Moreover, before the
start of the study, parents of all the participants were in-
formed of the study’s purpose and the procedure. We
obtained verbal consent prior to administering the ques-
tionnaires. Because of using non-invasive approach at
this study, we did not obtain written consent form. After
completing the first part of the questionnaire, which in-
cluded questions about the socio-demographic charac-
teristics of the children and their parents along with
some questions on their history of experiencing adverse
events while receiving the last dose of pentavalent vac-
cine, we gave parents an information sheet that included
questions related to the vaccination. After each vaccin-
ation (i.e. at 2, 4 and 6 months), they were asked to rec-
ord any complications they observed in the children
within the 48 h following the vaccination. After 48 h, we
contacted parent by telephone to complete the second
part of questionnaire. In total, we asked about the occur-
rence of 12 complications: (1) swelling, (2) redness, (3)
pain, (4) mild fever, (5) high fever, (6) drowsiness, (7) an-
orexia, (8) restlessness, (9) vomiting, (10) long-term cry-
ing, (11) encephalopathy and (12) convulsion using
standard definitions.
If parents reported a suspected occurrence of convul-
sion in the child, they were asked additional probing
questions about all the symptoms they observed in the
vaccinated child so that a specialist could make a defin-
ite conclusion concerning the occurrence of convulsion
afterward. In a similar way, parents could report on
other serious complications such as persistent crying
and irritability. Parents were asked to report possible ad-
verse events that they remembered in the case of a pre-
vious dose pentavalent/DTP vaccine. All children who
received the first, second and third doses of the vaccine
were followed up on by their parents (who were 98%
mothers) 48 h after immunization to determine the inci-
dence of complications.
The cumulative incidence of the outcomes studied (i.e.
the adverse events after pentavalent immunization) were
calculated with 95% confidence intervals (CI). Moreover,
risk ratio (RR) was calculated by dividing the cumulative
incidence of adverse events among male children to fe-
male children to explore gender differences. Chi-squared
tests and logistic regressions were used to investigate the
determinants of vaccine-related side effects. RR values
have been approximated using logistic regression
analysis. All statistical analyses were conducted at a
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significance level of 0.05 using SPSS software, version 20
(SPSS, Chicago, IL, USA).
Results
In this study, of the children who received pentavalent
vaccines in four health centers in Hamadan, 1119 chil-
dren were included in the study for the final analyses,
and all the pertinent data for these children were
collected after they received three doses of pentavalent
vaccine at 2, 4 and 6 months of age. The numbers of
children at the first, second and third doses of vaccine
were reported to be 373 (33.3%), 372 (33.2%) and 374
(33.4%), respectively. Moreover, 54.3% of vaccine recipi-
ents (n = 608) were male, whereas the remaining 45.7%
(n = 511) were female. The present study demonstrated
that the incidence rate of adverse events 48 h after
pentavalent immunization in the children under study
was estimated to be 15.8% (13.7–18.0) for swelling,
10.9% (9.2–12.9) for redness, 44.2% (41.2–47.2) for pain,
12.6% (10.7–14.6) for mild fever, 0.1% (0.0–0.4) for high
fever, 20.0% (17.7–22.5) for drowsiness, 15.0% (12.9–17.2)
for loss of appetite, 32.9% (30.2–35.8) for irritability, 4.6%
(3.4–6.0) for vomiting and 5.5% (4.2–7.0) for persistent
crying. However, there was no evidence for the occurrence
of convulsion and encephalopathy among children who
received vaccines. Table 1 presents the frequency of reac-
togenicity following immunization with pentavalent vac-
cine in the study group based on gender. The only
significant gender differences were found with regard to
persistent crying: the incidence of this complication in
males was higher than in females (p = 0.01). We found no
other significant gender differences in the incidence of
other complications.
With regard to the vaccine dose, the results of statis-
tical analyses indicated that the frequency of adverse
events due to pentavalent immunization in our sample
were statistically significant for swelling (p = 0.002), pain
(p = 0.002) and mild fever (p = 0.004). As shown in
Table 2, more fine-grained analyses revealed that the fre-
quency of swelling (p = 0.003), pain (p = 0.001), mild
fever (p = 0.003) and redness (p = 0.02) were signifi-
cantly higher after the first dose of vaccination com-
pared to the second dose, but that children were more
restless after the second dose than after the first
(p < 0.001). Furthermore, the symptoms of mild fever
were significantly higher in the third dose than in the
second dose ((p < 0.001).
In this study, we further examined the relationship be-
tween sex and adverse events following pentavalent vac-
cination by means of logistic regressions. As shown in
Table 1, the results of the analyses indicated that there is
no association between sex and adverse events following
pentavalent vaccination. Furthermore, we examined the
relationship between vaccination dose (i.e. first, second
and third dose) and adverse events following pentavalent
vaccination. As shown in Table 3, there is a statistically
significant relationship between the vaccination dose
and swelling (RR = 0.72 (95% CI: 0.59–0.89) and pain
(RR = 0.85 (95% CI: 0.74–0. 99). These complications
decrease with increasing age.
Discussion
The implementation of immunization is meant to protect
individuals and society as a whole against vaccine-
preventable diseases. Although advances in medicine have
made vaccines reliably more effective with minimal ad-
verse events, no vaccine can be found that is free from un-
wanted adverse events [11]. As the immunization
schedule for Hib is similar to that of the DTP vaccine, it
can be easily incorporated into the current immunization
program [14]. There has been no report of incompatibility
between the Hib vaccine and the DTP and hepatitis B
vaccines. In general, each new combination vaccine con-
taining the DTP vaccine is acceptable if there is no inter-
ference among multiple antigens. Physical and chemical
interactions among the components of a combination vac-
cine and immunological interference may trigger undesir-
able changes in the immune response to vaccines [15].
Hence, in this study, we attempted to investigate the
incidence rate of adverse events following immunization
associated with pentavalent vaccine, which has been im-
plemented as a combination vaccine in Iran for the first
time. To the best of our knowledge, this is the first study
that aims to provide evidence regarding the safety of
pentavalent vaccine in Iran.
The results obtained in the present study showed that
the most frequently reported reactogenicity associated
with pentavalent vaccine was pain, with an incidence
rate of 44.23%. This finding is in line with the results ob-
tained by Edna in his meta-analysis, in which some
minor reactions such as pain and redness were more
prevalent among the children who received the com-
bined vaccine [16]. The results of a study conducted in
China revealed that the majority of the adverse events
following immunization were reported to be non-serious
events; fever and injection site reaction were the most
common forms of reactogenicity experienced after
immunization [17]. Moreover, in other Iranian studies
on the adverse events associated with DTP and pentava-
lent vaccination, mild fever was found to be the most
commonly experienced complication that occurred after
vaccination [18–20]. Contrary to the above observation,
in our study, the incidence rate of mild fever was a re-
ported 12.2%. The main reason for the difference could
be the use of acetaminophen prior to vaccination and a
lack of sufficient parental attention to the child’s
temperature. We observed no significant difference in
the incidence rate of complications following vaccination
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between male and female children except for persistent
crying, which was significantly more common among
males than females.
We have cited some studies that assessing adverse
events associated with the pentavalent vaccine with a
separate formula or combinations. In a safety study
among Indian infants [21], authors have monitored ad-
verse events following a hexavalent vaccine during 1
month after immunization. They found that 37.9% in-
fants experienced at least one injection site reaction.
The corresponding value for systemic reaction was
54.6%. Wang YX et al. [22] in a clinical trial to evalu-
ation the safety of a “combined Haemophilus influenzae
type b-Neisseria meningitidis serogroup A and C-
tetanus toxoid conjugate vaccine (Hib-MenAC)” found
that there is no serious adverse events following im-
munization with Hib-MenAC. In a retrospective cohort
study, Sadoh AE and his/her colleagues [23] have com-
pared the prevalence of adverse events following penta-
valent and DTP vaccines in Nigeria. They reported that
the rate of pentavalent-related adverse reactions vaccine
was higher than DTP one (22.2% vs. 13.5%). Similar
studies in Iran have been implemented on different
antigen [24].
A comparison of the complication incidence rates of the
first and second doses of vaccination with pentavalent
showed that all the adverse events were more frequently
observed in the first dose of vaccination than the second,
Table 1 The cumulative incidence rate of adverse events associated with pentavalent vaccination in male and female children and
related risk ratios
Adverse events Incidence (per 100 children) P-value Risk ratio
(95% CI)aSex
Male Female
Swelling Yes 103(16.9) 74(14.5) 0.149 1.16 (0.88–1.50)
No 505(83.1) 437(85.5)
Redness Yes 64(10.5) 59(11.5) 0.327 0.91 (0.65–1.27)
No 544(89.5) 452(88.5)
Pain Yes 282(53.6) 213(41.7) 0.065 1.11 (0.97–1.27)
No 326(53.6) 298(58.3)
Mild fever Yes 75(12.3) 66(12.9) 0.420 0.95 (0.70–1.30)
No 533(87.7) 445(87.1)
High fever Yes 0 1(0.2) 0.457 NA
No 608(100) 510(99.8)
Drowsiness Yes 123(20.2) 102(20) 0.486 1.01 (0.80–1.28)
No 485(79.8) 409(80)
Anorexia Yes 91(15) 77(15.1) 0.514 0.99 (0.75–1.31)
No 517(85) 434(84.9)
Restlessness Yes 204(33.6) 165(32.3) 0.351 1.03 (0.87–1.22)
No 404(66.4) 346(67.7)
Vomiting Yes 29(4.8) 23(4.5) 0.474 1.05 (0.62–1.80)
No 579(95.2) 488(95.5)
Long-term crying Yes 43(7.1) 19(3.7) 0.010 1.90 (1.13–3.22)
No 565(92.9) 492(96.3)
Encephalopathy Yes 0 0 1 NA
No 608(100) 511(100)
Convulsion Yes 0 0 1 NA
No 608(100) 511(100)
History of convulsion Yes 3(0.49) 0 0.43 NA
No 605(99.5) 511(100)
Family history of convulsion Yes 10(1.64) 10(1.9) 0.16 0.84 (0.35–2)
No 598(98.3) 501(98.0)
NA not applicable
aFemale gender was considered as reference for RR calculation
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and this relationship was statistically significant. The only
exception was restlessness, which had a higher incidence
rate in the second dose of vaccination rather than the first.
The meaningful reduction in the incidence rate of these
complications with increasing age can be partly accounted
for by several factors, including the increase of muscle tis-
sue and deeper intramuscular injections. Moreover,
mothers might be more sensitive and worried about the
complications their children show after the first dose of
vaccination and thus give more detailed reports of the
complications their children experience after the first dose
of vaccination than after subsequent doses. In addition,
due to the experience they have gained after the first dose
of the vaccination, some mothers may use acetaminophen
prior to subsequent doses. The results of the statistical
analyses showed that with the exception of mild fever,
Table 2 Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children
Adverse events Incidence (per 100 children) vaccine dose P-value











Swelling 79(0.21) 50(0.13) 48(0.12) 0.003 0.068
Redness 50(0.13) 30(0.08) 43(0.11) 0.026 0.679
Pain 190(0.5) 143(0.38) 62(0.43) 0.001 0.162
Mild fever 45(0.12) 33(0.08) 63(0.16) 0.068 <0.001
High fever 1(0.002) 0(0) 0(0) 0.388 NA
Drowsiness 83(0.22) 72(0.19) 70(0.18) 0.310 0.725
Anorexia 65(0.17) 51(0.13) 52(0.13) 0.126 1
Restlessness 35(0.06) 115(0.3) 119(0.31) <0.001 0.766
Vomiting 16(0.04) 19(0.05) 17(0.04) 0.510 0.510
Long-term crying 24(0.06) 16(0.04) 22(0.05) 0.210 0.510
Encephalopathy 0(0) 0(0) 0(0) NA NA
Convulsion 0(0) 0(0) 0(0) NA NA
History of convulsion 0(0) 1(0.002) 2(0.005) 0.387 0.488
Family history of convulsion 0(0) 14(0.037) 6(0.016) <0.001 0.074
NA not applicable
Table 3 Relationship between vaccination dose and the cumulative incidence rate of adverse events associated with pentavalent
vaccine in children







Swelling 79(44.6) 50(28.2) 48(27.1) 0.72(0.59–0.89)
Redness 50(40.7) 30(24.4) 43(35) 0.9(0.72–1.14)
Pain 190(38.4) 143(28.9) 162(32.7) 0.85(0.74–0.99)
Mild fever 45(31.9) 33(23.4) 63(44.7) 1.24(1.00–1.54)
High fever 1(100) 0(0) 0(0) NA
Drowsiness 83(36.9) 72(32) 70(31.1) 0.89(0.74–1.07)
Anorexia 65(38.7) 51(30.4) 52(31) 0.87(0.71–1.06)
Restlessness 135(36.6) 115(31.2) 119(32.2) 0.9(0.77–1.05)
Vomiting 16(30.8) 19(36.5) 17(32.7) 1.02(0.73–1.44)
Long-term crying 24(38.7) 16(25.8) 22(35.5) 0.94(0.69–1.29)
Encephalopathy 0(0) 0(0) 0(0) Not applicable
Convulsion 0(0) 0(0) 0(0) Not applicable
History of convulsion 0(0) 1(0.2) 2(0.5) 3.45(0.5–23.74)
Family history of convulsion 0(0) 14(3.7) 6(1.6) 1.6(0.9–2.83)
NA not applicable
aRisk ratios values have been approximated using logistic regression analysis
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which was more common in the third dose of vaccination
than the second one, there was no significant difference
between the incidence rate of all other complications after
the second and third doses.
Study limitations
One limitation of the present study is that the limited sam-
ple size and the rarity of more serious complications such
as convulsion, encephalopathy and persistent crying con-
strain the generalizability of the study results. Other limita-
tions are the duration of follow up participants and lack of
control group. It is evident that some of rare adverse events
such as encephalopathy occur after 7–10 days following
immunization or later. Therefore, similar studies with long
duration follow up, larger sample sizes or the use of surveil-
lance system data associated with adverse events after
immunization are recommended. Consider to the above
mentioned limitations, findings on mild and moderate reac-
tions after pentavalent vaccine in this study as a field work
in the new setting could support licensur studies.
Conclusion
In general, the present findings on usual reactions should
move immunization programs to use pentavalent vaccina-
tions and continue implementing the current immunization
program in children under 1 year of age. Moreover, the
findings of this study show that giving some useful guide-
lines to parents with children under 1 year of age about
avoidable adverse events following vaccination such as pain,
redness and swelling is a necessary measure for effectively
managing these complications.
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